Itromiz-SB 130 Capsule contains Itraconazole 130 mg, a broad-spectrum triazole antifungal agent used for the treatment of various fungal infections. Itraconazole exerts its antifungal activity by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, which is essential for the synthesis of ergosterol, a key component of fungal cell membranes. This disruption leads to increased membrane permeability and ultimately fungal cell death. Itromiz-SB 130 Capsule is indicated for the management of systemic and superficial mycoses, including aspergillosis, blastomycosis, histoplasmosis, onychomycosis, and candidiasis. The drug is well-absorbed orally, with enhanced bioavailability when taken with food, and is extensively metabolized in the liver. It is contraindicated in patients with known hypersensitivity to itraconazole or other azole antifungals and should be used cautiously in individuals with hepatic impairment or congestive heart failure. Common adverse effects include gastrointestinal disturbances, headache, and rash. Drug interactions are significant due to itraconazole’s inhibition of CYP3A4 enzymes, necessitating careful review of concomitant medications. Itromiz-SB 130 Capsule should be administered under medical supervision with appropriate monitoring to ensure efficacy and minimize potential toxicity.